No Data
Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating
Express News | Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program
Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20
Zacks.com Featured Highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
QMengColdJoke : I am buying back, this designation itself means nothing but in the end will make final approval easier and faster.